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units. The AIR increased seromucoids to 95.1±5.7 vs 8.4±1.6mg/dl
in controls (p< 0.05). The AIR reduced CYP3A6 activity to 5972±464,
5415±541 and 2639±747, and CYP1A2 activity, 3026±113, 3856±1151,
3805±753 for control, 20 and 30 days of CS, respectively (p< 0.05
compared without AIR). CS did not affect NADPH activity or expression.
Conclusions: It is concluded that CS does not affect activity or expres-
sion of CYP3A6 and CYP1A2, nor prevents AIR-induced down-regulation.
These results are in agreement with the absence of CS-drug interactions
in humans.
534 SIX-MONTH EFFICACY OF INTRA-ARTICULAR HYALURONIC
ACID FOR CARPOMETACARPAL JOINT OSTEOARTHRITIS
M. Massarotti, F. Uboldi, E. Valcamonica, L. Belloli, B. Marasini.
Rheumatology Unit, IRCCS Humanitas Clinical Institute, University of
Milan, Rozzano (Milan), ITALY
Purpose: To investigate the six-month efﬁcacy of a three intra-articular
hyaluronic acid (HA) injection course on pain relief in osteoarthritis (OA)
of the carpometacarpal joint (CMC).
Methods: Thirty-nine female patients affected by symptomatic CMC OA
(aged 66±8 years, mean±SD) were treated with three once-weekly intra-
articular injections of HA (Hyalgan 1ml). All subjects met ACR criteria
for hand OA and had CMC OA grade 1−4 according to Kellgren and
Lawrence on standard X-ray performed within 6 months before the
inclusion. Fifty-nine CMC joints were treated and evaluated (twenty-three
patients underwent to bilateral injections, thirteen patients had only one
hand treated). Patients were followed for a 6-month period after the last
injection. Treatment efﬁcacy was assessed through visual analogue scale
(VAS) pain quantiﬁcation (baseline; 2nd and 3rd injection; one, three and
six months after the last injection). Side effects were recorded.
Results: VAS was signiﬁcantly reduced after the ﬁrst injection (2nd
injection vs baseline, p< 0.01; 3rd injection vs baseline, p< 0.0001;
3rd injection vs 2nd injection, p< 0.05) and reached the slowest score
one month after the last injection. The efﬁcacy was maintained for all
the 6-month follow-up period (one month vs baseline, p< 0.0001;three
months vs baseline, p< 0.0001; six months vs baseline, p = 0.0001 – one
month vs 3rd injection, p = n.s.;three months vs 3rd injection, p = n.s.; six
months vs 3rd injection, p = n.s.). Only minor side effects were observed
(mild pain and/or ecchymosis in injection site).
Conclusions: Our study supports viscosupplementation with HA as a
safe and efﬁcacious approach for symptomatic CMC OA. Our schedule
based on three weekly intra-articular injections supplies pain relief lasting
as long as 6 months with negligible side-effects.
Further studies are needed to determine the long-term efﬁcacy and the
optimal treatment schedule.
535 TWELVE WEEKS MULTIMODAL CONSERVATIVE TREATMENT
OF KNEE OSTEOARTHRITIS USING A NEWLY DEVELOPED
TREATMENT PROTOCOL IN THE NETHERLANDS:
PRELIMINAIRY RESULTS
G.F. Snijders, A.A. den Broeder, C.H. van den Ende, F.H. van den
Hoogen. Sint Maartenskliniek, Nijmegen, NETHERLANDS
Purpose: Recently extensive evidence based recommendations have
been made in the Netherlands for diagnosis and treatment of knee and hip
osteoarthritis (OA). Based on this a three months standardized treatment
protocol was developed including education, advice about weight loss
and lifestyle measures, use of analgetics, referral for physical therapy
and when necessary other interventions like intra-articular injections. To
implement this protocol an outpatient clinic was initiated for conservative
treatment of primary osteoarthritis of the knee. The aim of this study was
to assess the results of a standardized conservative treatment protocol
for knee OA.
Methods: Patients with symptomatic clinical knee OA according to the
ACR classiﬁcation criteria referred to the rheumatology department by
general practitioners were treated at the outpatient clinic of the Sint
Maartenskliniek. In addition to patient education, treatment consisted of
three main modalities: stepwise analgesia, referral to exercise therapy
using ‘graded activity principle’ and weight reduction advises if necessary.
Visits took place at the outpatient clinic at intake and after 12 weeks;
patients were contacted by telephone at 4 and 8 weeks. Pain and ADL
function were measured using a Likert scale (0−10) for pain and patient
global assessment (PGA) and using WOMAC compatible subscales of
the Knee injury and Osteoarthritis Outcome Score (WKOOS) (Likert
scale version). WKOOS based OMERACT-OARSI responder criteria were
measured in all patients after twelve weeks. Finally kinesiophobia was
measured using the Tampa Scale of Kinesiophobia (TSK).
Results: Fifteen patients (13 females, mean age (±SD) 62±12) were
thus far included. At intake the following values were found (mean±SD):
pain and PGA 6.1±1.9 and 6.1±2.5 respectively, WOMAC compatible
subscales for pain, stiffness and function 11±4.4, 4.5±1.5 and 38±14
respectively, BMI 34.4±4.8 and TSK scores 40±6 (cut-off for irrational
kinesiophobia >37). After twelve weeks pain, PGA, BMI and TSK did
not change signiﬁcantly: scores were 6.4±3.2 (p = 0.8), 6.2±2.7 (p = 0.9),
33.7±5.0 (p = 0.09) and 39±5 (p = 0.3) respectively. WKOOS based
OMERACT-OARSI responder criteria were however met in 40% of the
patients.
Conclusions: Although 40% of patients met the OMERACT-OARSI re-
sponder criteria using this protocol, mean pain and ADL function did not
change, indicating that a subgroup of patient worsened. However, this
sample probably reﬂects a highly selected population. Future research
should be directed at identifying prognostic factors for non-response such
as body weight and kinesiophobia.
536 EFFECTS OF EXOGENOUSLY INJECTED HYALURONAN ON
THE ARTICULAR CARTILAGE IN A RAT IMMOBILIZED KNEE
MODEL
A. Ando, Y. Hagiwara, E. Chimoto, Y. Onoda, H. Suda, E. Itoi. Tohoku
University, Sendai, JAPAN
Purpose: Joint immobilization is an essential treatment in daily exami-
nations but it also causes degeneration of the articular cartilage. Intra-
articular hyaluronan (HA) injection is widely used as a treatment of
osteoarthritis (OA) due to its physical and biological activities. Though
a large number of studies regarding chondroprotective effects of HA on
OA animal models have been reported, most of these are based on joint
instability models by resection of ligaments or meniscus. There were few
reports of the effects of HA regarding immobilized joints. In this study, we
examined the chondroprotective effects of exogenously administered HA
in a rat immobilized knee model.
Methods: Animals: A total of 84 adult male Sprague-Dawley rats weigh-
ing from 380–400 g were used. Their unilateral knee joints were immo-
bilized rigidly at 150º in ﬂexion with a plastic plate and metal screws
placed internal but extra-articularly for various periods (1, 2, 4, 6, 8,
12, and 16 weeks). 50 ml of HA (molecular weight = 1.9×106) was
administered intra-articularly for HA group on the day after surgery
and once a week until euthanasia. The same amount of saline was
administered for control group. Tissue Preparation: The specimens were
ﬁxed with 4% paraformaldehyde. After decalciﬁcation and dehydration,
the specimens were embedded in parafﬁn. The embedded tissue was
cut into 5mm sagittal sections. Standardized serial sections were created
in the medial midcondylar region of the knee. Histological Evaluation:
We chose 3 areas (non-contact, transitional, and contact area) from the
articular surface of the femur and tibia. A degree of degeneration in each
section from the 6 areas was evaluated respectively using the histological
grading scheme (modiﬁed Mankin’s score). The thickness of the total
articular cartilage was measured and the number of chondrocytes was
counted in each area, respectively.
Figure 1. Femur contact area 16 weeks.
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Figure 2. Modiﬁed Mankin’s Score.
Figure 3. Number of chondrocytes.
Results: Degeneration of the articular cartilage was observed in the
three areas in both groups, but the change in each area was different.
Histological grading scores in the hyaluronan group were smaller at 12
and 16 weeks compared with that in the saline group (Figure 1, 2). The
thickness of the articular cartilage in the non-contact and contact areas
was unchanged, but it was increased in the transitional area in both
groups. The number of chondrocytes in the contact and transitional areas
was decreased in both groups, but the number in the hyaluronan group
was greater at 12 and 16 weeks compared with that in the saline group
(Figure 3).
Conclusions: HA has chondroprotective effects on the articular cartilage
in a rat immobilized knee model, especially for the number of chondro-
cytes. This result may be due to anti-apoptotic effects of HA on the
articular cartilage.
537 INFLIXIMAB (IFX) MIGHT BE PROTECTIVE AGAINST
PROGRESSIVE RADIOGRAPHIC INTERPHALANGEAL
OSTEOARTHRITIS (OA)
M. Gu¨ler-Yu¨ksel1, M. Kloppenburg1, C.F. Allaart1, I. Watt1,
B.A. Dijkmans2, T.W. Huizinga1, W.F. Lems2. 1LUMC, Leiden,
NETHERLANDS, 2VUMC, Amsterdam, NETHERLANDS
Purpose: To investigate the association between inﬂammation and the
incidence and progression of interphalangeal OA and the effect of IFX on
interphalangeal OA.
Methods: Data from patients from the BeSt study with X-rays available
were utilized. In the BeSt study 508 recent-onset rheumatoid arthritis
(RA) patients were randomized into 4 treatment strategies: 1. sequential
monotherapy, 2. step-up combination therapy, 3. combination therapy with
prednisone and 4. IFX and methotrexate (MTX). In groups 1−3, patients
proceeded to treatment with IFX and MTX after failing on at least 3 pre-
vious DMARDs. The IFX dose varied between 3 and 10mg/kg/8 weeks.
X-rays of the hands were scored random in time for osteophytes (grade
0−3 for each joint) using the Osteoarthritis Research Society International
atlas in 10 DIP joints (DIPJs) and 8 PIP joints (PIPJs) at baseline and after
3 years. The incidence and progression of OA was deﬁned as a change
from baseline in the osteophyte score greater than SDC (1.7 units) in
patients without and with one or more osteophytes at baseline. Erosions
were measured according to the Sharp-van der Heijde score.
In multivariate analyses, adjusted for age, gender, postmenopausal status
and BMI, associations between the components of the DAS and erosion
scores and the incidence and progression of interphalangeal OA was
determined.
Results: 416 patients (67% women, mean age 54 years) were included.
At baseline, osteophytes were present in 37% of the patients in one
or more DIPJs and in 13% of the patients in one or more PIPJs. After
3 years, 6 and 4% of the patients had incident OA in the DIPJs and PIPJs.
Radiographic progression was present in 18 and 15% of the patients in
the DIPJs and PIPJs. Number of swollen joints at baseline, erosion score
at baseline, change in erosion score after 3 years and postmenopausal
status were associated with incidence of interphalangeal OA. Change
in erosion scores after 3 years was associated with progression of
interphalangeal OA.
178 (43%) patients were treated with IFX during some period of the study
and these patients had less incident OA (4% in patients who received
IFX versus 7% in patients who did not receive IFX, p = 0.211) and less
progressive OA (10 versus 38%, p = 0.020) in the PIPJs. Combination
therapy with IFX did not affect the incidence of OA (7 versus 7%,
p = 0.974), nor the progression (29 versus 24%, p = 0.516) in the DIPJs.
Conclusions: The incidence and progression of interphalangeal OA was
associated with more inﬂammatory activity in RA patients, suggesting that
inﬂammation might play a role in the pathogenesis of interphalangeal OA.
Combination therapy with inﬂiximab reduced the progression of OA in the
PIPJs in the period of three years after baseline, suggesting that anti-TNF
might be an effective treatment against hand OA.
538 REPORT FROM ITALIAN NATIONAL REGISTER: REDUCTION
IN NSAIDS CONSUMPTION AFTER INTRA-ARTICULAR
INJECTIONS OF HYALURONIC PRODUCTS IN PATIENTS
WITH SYMPTOMATIC HIP OSTEOARTHRITIS
A. Migliore1, E. Bizzi1, U. Massafra1, S. Tormenta1, M. Granata2,
M. Massarotti3, G. D’Avola4, R. De Chiara5, M. Ranieri6, C. Maggi7.
1S. Pietro FBF Hospital, Rome, Italy, Rome, ITALY , 2S. Filippo Neri
Hospital, Rome, Italy, Rome, ITALY, 3Humanitas Clinical Institute,
Rozzano, Milan, ITALY, 4ASL 3, Catania, ITALY, 5University of Lamezia
Terme, Lamezia Terme, Catanzaro, ITALY, 6Velletri Hospital, Velletri,
Rome, ITALY, 7Ortotrauma Hospital, Stradella, Pavia, ITALY
Purpose: Clinical reports showed that intra-articular treatment with
Hyaluronic products is safe and effective for treatment of Knee os-
teoarthritis (OA). Similar results appeared in some reports about treat-
ment of hip OA, but data are scarce due to the difﬁculties associated
with the injection technique which requires use of X-ray or ultrasound
(US) guidance. We report from the Italian national database of ANTIAGE
(National Association for Ultrasound Guided Intra-articular Treatment of
Hip) about reduction of NSAID intake after intra-articular injection with
hyaluronic products in patient with hip OA.
Methods: 1887 adults, ambulatory patients with hip OA, selected from
February 2004 to April 2008, underwent to intrarticular injections, per-
formed with US guidance, according to Migliore-Tormenta technique.
Every six months patients were injected with several products, Low and
High MW, like Hylan GF-20 (2ml), Hyalgan (4ml), Hyalubrix, (4ml) and
Jointex (4ml). Monthly NSAID intake, by measuring the number of days
the patient had used NSAID during the previous month, was evaluated
at baseline and every three months. Follow-up period was of 42 months.
A multivariate analysis with Wilcoxon test was performed.
Figure 1. NSAID consumption. p< 0.001 for every value obtained at
follow-up when compared with baseline value.
Results: 1887 patients were injected. We found a statistical reduction
of NSAID already after the ﬁrst injection (p< 0.001), decreasing from
7.37 days per patient at baseline to 3.84 after 6 months from the ﬁrst
injection (Fig. 1). The reduction in NSAID consumption obtained was
